Table 3.
LogC0/D | n | Month 6 | Month 9 | Month 12 | Total Means | 95% CI a |
---|---|---|---|---|---|---|
CYP3A5 expressers | 110 | 0.03 ± 0.18 | 0.04 ± 0.17 | 0.05 ± 0.17 | 0.04 b | 0.01, 0.07 |
CYP3A5 nonexpressers | 78 | 0.32 ± 0.18 | 0.34 ± 0.17 | 0.36 ± 0.19 | 0.34 b | 0.30, 0.38 |
Total means | - | 0.18 c | 0.19 | 0.20 c | - | - |
95% CI a | - | 0.15, 0.20 | 0.17, 0.22 | 0.18, 0.23 | - | - |
Source | Sum of Squares | Mean square | df | F | p-Value | Partial eta-squared |
CYP3A5*3 polymorphisms | 12.2 | 12.2 | 1, 186 | 158 | <0.001 | 0.459 |
Time | 0.072 | 0.039 | 1.85, 345 | 4.02 | 0.021 | 0.021 |
Polymorphisms × Time | 0.005 | 0.003 | 1.85, 345 | 0.279 | 0.740 | 0.001 |
LogC0/D, logarithms of dose-adjusted trough concentrations of tacrolimus in ng/mL per mg/day. a 95% confidence interval of total means. b p < 0.001 for comparison between CYP3A5 expressers and nonexpressers. c p < 0.05 for comparison between month 6 and month 12 (Bonferroni correction).